Adherence to physical activity guidelines throughout chemotherapy was associated with better self-reported cognition.
Researchers identified prognostic factors for improved overall survival in patients treated with palbociclib and fulvestrant for advanced breast cancer.
Editorialists questioned the quality of the data set.
In 2019, the FDA granted accelerated approval to Tecentriq, a PD-L1 blocking antibody, for unresectable locally advanced or metastatic TNBC.
Eight percent drop in screenings at 32 community health centers means about 47,517 fewer mammograms, 242 missed breast cancer diagnoses
Drop in breast cancer screenings at one safety-net hospital raises concerns for worsening of preexisting health disparities.
Both models would have reduced false positives without missing any cancer cases.
Starting screening at age 40 was linked to a reduced risk of death and was deemed cost-effective.
Entinostat did not improve progression-free or overall survival.
Prior data suggested the incidence may be as high as 16%.